Table 6—

Summary of the variables analysed by the 13 studies reviewed

First author [Ref.]Variables included
Gandhi 9YesWYesS
Migliori 10YesYesYesYesWYesYesYesYesYesYesYesYesI
Migliori 11YesYesYesYesW/LYesYesYesYesYesYesYesYesYesI
Kim 12YesYesLYesYesYesYesYesIYesYes
Mitnick 16YesYesYesYesLYesYesYesYesYesYesYesYesYesIYes
Chan 17LYes
Keshavjee 19YesYesYesLYesYesYesYesYesYesYesIYesYes
Eker 18YesYesYesYesYesLYesYesYesYesYesYesYesYesYesIYesYes
Kwon 20YesYesLYesYesYesYesIYes
Lai 21YesYesYes
Banerjee 22YesWYesYesYesYesI
Bonilla 23YesYesYesLYesYesYesYesYesS/I
Kim 24YesYesYesYesWYesYesYesYesYesIYes
  • 1: representative sample (multidrug-resistant (MDR)-tuberculosis (TB) coverage); 2: history of previous treatment (MDR- versus extensively drug-resistant (XDR)-TB); 3: number with previous treatment for >1 month (MDR versus XDR); 4: number of drugs used in treatment (MDR versus XDR); 5: linezolid; 6: standard definitions according to Laserson et al. 28 (L) and/or the WHO (W); 7: number of drugs to which strains were resistant (MDR versus XDR); 8: 100% supranational reference laboratory quality assurance drug susceptibility testing; 9: all XDR-defining drugs tested; 10: times to sputum smear and/or culture conversion; 11: treatment success (MDR versus XDR); 12: failure (MDR versus XDR); 13: death (MDR versus XDR); 14: follow-up; 15: prevalence of HIV; 16: standard (S) or individualised (I) treatment; 17: surgery reported; 18: adverse events reported.